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Purpose: Leiomyosarcoma (LMS) of the inferior vena cava (IVC) is a rare primary soft tissue sarcoma. Few reports have de-
tailed the tumor features, treatment strategies, and long-term outcomes in IVC LMS patients. The present report describes 
the treatment and long-term outcomes of six patients with IVC LMS. Methods: We reviewed six consecutive cases of IVC 
LMS treated at the University of Ulsan College of Medicine, Asan Medical Center from August 1998 to June 2010. Results: 
The patients comprised five females and one male, and had a median age of 44 years (range, 25 to 64 years). All tumors were 
suprarenal. The tumors were located between the hepatic and renal veins (i.e., middle segment; n = 5 [83%]), or above the 
hepatic veins (i.e., upper segment; n = 1 [17%]). Prosthetic IVC replacement using polytetrafluoroethylene grafts was per-
formed in five patients, and the remaining patient underwent only tumor resection and IVC ligation. There were no intra-
operative or postoperative deaths. The mean tumor size was 9.3 cm (range, 5 to 20 cm), and five of the six tumors were high 
grade. The mean follow-up period was 80 months (range, 6 to 118 months). The median survival period was 94 months. 
Recurrence occurred in all patients. Distant recurrence resulted in three patients undergoing lung resection and three pa-
tients undergoing thigh muscle resection. Conclusion: IVC LMS is a rare but serious disease. Although surgical resection 
combined with chemoradiotherapy was not completely curative, it resulted in long-term patient survival, even in patients 
with advanced tumors.
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INTRODUCTION
Leiomyosarcoma of the inferior vena cava (IVC) can be 
a fatal disease. Although leiomyosarcoma is the most com-
mon primary malignancy of the IVC, it is a rare condition, 
with fewer than 300 cases reported, and most studies are 
limited to single case reports or compilations of case series. 
As a result, there is inadequate information regarding IVC 
leiomyosarcoma prognostic factors due to the lack of data 
regarding tumor characteristics, treatment strategies and 
long-term outcomes. 
En bloc tumor resection is the only treatment option that Jihoon T Kim, et al.
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Fig. 1. Preoperative leiomyosar-
coma (LMS) evaluation. LMS were 
preoperatively assessed using veno-
graphy computed tomography scan, 
and venographic biopsy.
can provide long-term survival for IVC leiomyosarcoma 
patients. According to the international register estab-
lished by Mingoli et al. [1], the 5- and 10-year actuarial ma-
lignancy-free survival rates after wide surgical resection 
are very low. Debate continues regarding the optimal 
management of the IVC after tumor resection, with pri-
mary repair, ligation and IVC reconstruction all having 
been utilized with varying success. The efficacy of ad-
juvant therapy (chemotherapy or radiotherapy) has not 
been established. In addition, no study has clearly ad-
dressed the management of recurrent disease. 
The present study describes the treatment of six IVC 
leiomyosarcoma patients in our center. All patients under-
went surgical resection and adjuvant therapy. Patients 
were followed for up to 118 months. We analyzed treat-
ment regimens, tumor pathology, recurrence and out-
comes in these patients. 
METHODS
The present study reviewed six cases of IVC leiomyo-
sarcoma treated at the Asan Medical Center between 
August 1999 and June 2010. Clinical and pathologic data, 
surgical management, and outcomes were assessed. The 
study was approved by our institutional review board. 
IVC segments were defined as follows: upper segment = 
from the right atrium to the hepatic veins, middle segment 
= below the hepatic veins to the renal veins, and lower seg-
ment = below the renal veins to the bifurcation of the IVC. 
Symptom assessment was based on a review of the rele-
vant medical records. Operative notes and pathology re-
ports were used to collect data regarding the tumor, the or-
gans resected en bloc, and post-resection IVC manage-
ment. 
All patients underwent contrast-enhanced computed 
tomography (CT) scans of the abdomen and pelvis to as-
sess tumor resectability. The degree of caval obstruction 
and development of collateral vein circulation was eval-
uated using cavography in four patients. Venographic bi-
opsies were performed in four patients (Fig. 1). 
Patient survival data were obtained from medical 
records. Overall survival rates were calculated from the 
date of surgery to the date of death or last contact. 
Disease-free survival rates were calculated from the date 
of the first operation to the date of first recurrence. 
Disease-specific survival was estimated using the Kaplan- 
Meier life table.
Case 1
This patient is a female at her age 55. She came to the 
hospital with a repetitive abdominal pain having started 
three weeks ago. She did not have any underlying disease. 
In an abdominal ultrasonography at our hospital, a 7-cm 
abdomen-pelvis tumor was found, and it was thought to 
originate from the IVC.Outcomes of IVC leiomyosarcoma
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The patient got the resection of her IVC and left renal 
vein. Then using polytetrafluoroethylene (PTFE), an IVC 
replacement was operated, and an interposition was car-
ried out on the left renal vein to reconstruct it, and there 
was no resection of another accompanying organ.
The tumor was located in the middle segment, which 
was 7 cm. Pathologically the resection margin was secured 
to be negative. In a pathologic report, it was at a histo-
logical high grade; however, there was no necrosis, and the 
mitotic rate was good (＜3/10 HPF).
After the surgery, 5-cycle chemotherapy was carried out 
with adjuvant therapy, and the regimen of chemotherapy 
was a combination of dacarbazine, doxorubicin and cyclo-
phosphamide.
In the 76th month after the first surgery, a metastatic re-
currence took place on the right lung, so a right middle lo-
bectomy was performed, and a year after, it recurred on 
the right thigh muscle, so a wide excision, and chemo-
therapy and radiotherapy with isofamide/cisplatin were 
performed again and then the patient survives stably 
without any special relapse until now.
Case 2
This patient is a female at her age 25. She visited another 
general hospital with an abdominal pain for four months 
and was diagnosed malignancy through a biopsy, and 
came to our hospital for a further evaluation and treat-
ment. The size of the tumor was 9 cm, located in the middle 
segment of IVC. Since the IVC and left renal vein were in-
volved, the IVC and left renal vein got resection during 
surgery. Then the IVC was replaced using a PTFE graft; 
however, since the left renal vein has sufficient collateral 
flow toward the gonadal vein, a ligation only was carried 
out. Negative resection margin was secured patholo-
gically. After the surgery, 6-cycle adjuvant chemotherapy 
was performed using epirubicin, ifosfamide and dacar-
bazine.
Eighteen months later, multiple recurrences were found 
in the patient’s right lung, kidney, and retroperitoneum. 
After two cycles of chemotherapy with cisplatin and ifos-
mide, and 6-cycle chemotherapy with the regimen of a 
combination of dacarbazine, doxorubicin, cyclophospha-
mide, and vincristine sulfate, a surgery to remove the re-
current tumor in the retroperitoneum was performed. For 
30 days after the second surgery, radiotherapy was carried 
out at a total 5,400 cGY; however, she died of multi-organ 
metastasis in the 36th month after the first surgery.
Case 3
This patient is a female at her age 63. She came in pre-
senting with chronic pain in her right abdomen. In a CT 
scan in our hospital, a 8 cm tumor was found. This tumor 
was located at the junction between the right renal vein 
and the IVC. After an excision of the IVC and right renal 
vein, an IVC replacement was carried out using a PTFE 
graft, and an interposition with PTFE graft was performed 
to reconstruct the right renal vein. During the surgery, 
there was invasion into the liver’s caudate lobe, so accom-
panying resection was carried out.
After the surgery, radiotherapy with a dose of 5,580 cGY 
was operated during 31 days while adjuvant chemo-
therapy was not carried out.
Forty-seven months after the surgery, wedge resection 
was performed for the right lung metastasis and three 
months later, the left lung metastasis was found again, so 
lobectomy of the left lower lobe was carried out. Then fol-
low-up failed, but 97 months after the surgery, it was con-
firmed finally that she died of multiple metastasis in an-
other hospital.
Case 4
This patient is a female at her age 57. She came to the 
hospital with her epigastric pain starting several months 
ago. A CT scan was shot and a mass which is considered 
starting from the IVC was found so a surgery was per-
formed. At the time, the mass was 5 cm, located in the mid-
dle segment of the IVC, and the left renal vein was in-
volved; however, there was no infiltration into another 
organ. After the resection of the IVC and the left renal vein, 
IVC replacement and interposition of the left renal vein 
were operated. However, a pathologic negative margin 
was not secured in a permanent report while the IVC’s 
naked-eye resection margin was secured. Adjuvant radio-
therapy was performed for 29 days with a total dose of 
5,300 cGY while chemotherapy was not carried out.
Ninety-one months after the surgery, wide excision was Jihoon T Kim, et al.
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carried out for the recurrence in the left thigh muscle, ra-
diotherapy was operated again, and since then, she has 
survived stably without any evidence of another relapse.
Case 5
This patient is a male at his age 36. He came to another 
hospital presenting with the back and abdominal pain, 
and low leg edema having started 5 months ago, and was 
transferred to our hospital with leiomyosarcoma in the 
IVC presented on a CT scan. In the operative opinion, the 
mass was located in the middle segment completely block-
ing the lumen. Because of the leiomyosarcoma showing an 
extra-luminal growing in the IVC origin, there was in-
volvement of both renal veins, without any infiltration to 
another organ. Since the IVC was at the status of complete 
obstruction, no replacement was made, and as the renal 
veins on both sides were also at the status of complete ob-
struction, the surgery was completed without any special 
reconstruction. Immediately after the surgery, there was 
neither complication except a temporary leg edema nor 
abnormality in the renal function. However, securing a 
pathological tumor free margin at the upper and lower 
margins failed.
After the surgery, adjuvant radiotherapy was operated 
with a dose of 5,640 cGY during  31 days while no chemo-
therapy was performed. Five months after the surgery, an 
intra-abdominal peritoneal single mass was found and 
excised. With a definite diagnosis as recurring mass, ra-
diotherapy was carried out again at the resection site. Ten 
months after the first surgery a small nodular metastasis 
was found in the right lower lung, and needle biopsy was 
performed and it got a definite diagnosis as metastatic 
nodule. However, the patient refused an operation, so 
6-cycle of chemotherapy with a combination of cisplatin, 
ifosfamide and etoposide were performed and it got a 
complete remission. However, in the 59th months after the 
first surgery, a left buttock mass was detected so radio-
therapy was carried out again. Five months later, on the 
CT scan and magnetic resonance imaging scan in a fol-
low-up observation, a nodule was found. It was thought to 
be a metastasis in the lung and lumbar spine. However, his 
reaction to radiotherapy was poor and it was considered a 
multiple small metastasis, so no additional treatment was 
performed and currently a follow-up observation is in 
progress. For about 2 years, he has survived at a stationary 
status without any significant aggravation.
Case 6
The patient is a female at her age 30. She had had upper 
abdominal pain since 5 months before she came to our hos-
pital and had come to another hospital as she felt leg ede-
ma and abdominal mass since 1 month ago. After having 
been diagnosed of the IVC tumor on a CT scan in the hos-
pital, she was transferred to ours. During the surgery, 
there was involvement from the iliac bifurcation to the su-
pra-hepatic IVC, and both renal veins also were invaded. 
Since there was direct invasion into the left hepatic vein, ex 
situ resection was carried out in the IVC along with the 
whole liver. After that, hepatic vein venoplasty was car-
ried out through a bench procedure, and then the IVC was 
replaced with a PTFE graft and auto-transplantation was 
carried out in the liver. Both renal veins were not re-
constructed and were left the status of ligation. Immedia-
tely after the surgery, there was no complication related to 
the surgery, and the renal function and the liver function 
were maintained without any problem. Adjuvant therapy 
was not carried out. 
Three months after the surgery, a multiple liver meta-
stases were found, and later 7-cycle chemotherapy was 
carried out with doxorubicin and ifosfamide, and since 
then as chemotherapy was carried out with several clinical 
trial medications, she has survived at a stationary status.
RESULTS
The six cases comprised five females and one male. The 
median patient age was 44 years (range, 25 to 64 years). 
The initial presenting symptoms included abdominal pain 
(n = 6, 100%), weight loss (n = 2, 33%), lower extremity ede-
ma (n = 2, 33%) and palpable mass (n = 1, 16%). All tumors 
were located above the renal vein, with five (83%) being in 
the middle segment, and one (17%) in the upper segment. 
That latter case involved the suprahepatic IVC and ex-
tended to the bilateral common iliac vein (Tables 1, 2). 
Complete gross resection of the tumor was undertaken in Outcomes of IVC leiomyosarcoma
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Patient no. Age/sex Location Tumor grade IVC management Concomitant procedure Time to recurrence Total survival
1  55/F Middle High PTFE replace None 67 132
2  25/F Middle Low PTFE replace None 18  36
3  64/F Middle High PTFE replace Caudate lobe 47  97
4  57/F Middle High PTFE replace None 91  97
5   36/M Middle High Ligation None   5  91
6 30/F High High PTFE replace Liver auto-transplantation   3  25
PTFE, polytetrafluoroethylene.
Table 1. Patient characteristics
Patient no. Presentation Venogram/biopsy  IVC obstruction symptoms Degree of IVC obstruction
1 Abdominal pain Yes/Yes None Partial
2 Abdominal pain palpable mass Yes/Yes None Complete
3 Abdominal pain Yes/Yes None Partial
4 Abdominal pain No/No None Partial
5 Abdominal Pain No/No Leg edema Complete
6 Abdominal pain palpable mass weight loss Yes/Yes Leg edema Complete
Table 2. Clinical findings at presentation
Fig. 2. A large leiomyosarcoma in 
the upper segment with middle 
hepatic vein involvement. The pa-
tient underwent ex situ excision with 
the whole liver and auto-transplan-
tation after venoplasty.
all six cases. For the upper segment tumor, the whole liver 
was removed and the tumor then excised ex situ. The re-
sected liver was then auto-transplanted using Bench veno-
plasty with an autologous vein graft, and the IVC was re-
placed with a PTFE prosthetic graft (Fig. 2). For middle 
segment tumors, leiomyosarcomas were resected in situ 
and PTFE grafts were used for prosthetic IVC replace-
ment. We didn’t use anti-coagulative agent or anti-platelet 
agent routinely. All PTFE graft has been keep patency dur-
ing follow-up period.  
One case showed that IVC was complete obstruction at 
the suprarenal level. That patient showed hemodynamic Jihoon T Kim, et al.
106 thesurgery.or.kr
Patient no.
Prosthetic IVC
replacement
Involve renal vein and 
related procedure
Postoperative course Postoperative stay (day)
1 PTFE replacement Rt. reimplantation
Lt. PTFE interposition
Hematoma/pancreatitis 14
2 PTFE replacement Rt. reimplantation
Lt. ligation
None 13
3 PTFE replacement Rt. PTFE interposition
Lt. reimplantation
None    9
4 PTFE replacement Rt. reimplantation
Lt. PTFE interposition
None   6
5 No Both ligation Transient leg edema   8
6 PTFE replacement Both ligation  None 17
IVC, inferior vena cava; PTFE, polytetrafluoroethylene; Rt, right; Lt, left.
Table 3. Surgical procedures and outcomes
Patient no. Tumor grade Necrosis 
Mitotic rate 
(/10 HPF) 
Resection margin
Vascular 
development 
Tumor size (cm)
1 High 0    3  Negative Intraluminal       7.3
2L o w ＋   7  Negative Extraluminal      8.9
3H i g h ＋  22 Negative Intraluminal   8
4H i g h ＋＋  15 Positive Extraluminal    5
5H i g h＋＋＋  12 Positive Extraluminal    8
6H i g h ＋＋  15 Negative Intraluminal  20
Table 4. Pathology findings
stability and maintenance of urine output during IVC 
clamping, had IVC total occlusion in association with ex-
tensive long-segment disease, and well-developed venous 
collaterals. That patient had normal renal function both 
pre- and postoperatively. 
At least one renal vein was ligated in three patients, both 
renal veins were ligated in two patients and one renal vein 
was ligated in one patient. None of those patients showed 
postoperative renal impairment. 
Organ en bloc removal with the primary tumor was per-
formed in 2 (33%) patients, comprising a partial hep-
atectomy in one patient and a whole liver ex situ excision 
followed by auto-transplantation in one patient. 
The mean length of hospital stay was 11 days. There 
were no intraoperative or postoperative deaths. Postoper-
ative morbidity comprised transitional leg edema in a pa-
tient who did not undergo IVC replacement, and hema-
toma and mild pancreatitis in another patient (Table 3). 
The mean tumor size was 9.3 cm (range, 5 to 20 cm). 
Three tumors (50%) grew endoluminally, and the other 
three grew exoluminally. Histological examination showed 
that there were five high-grade tumors and one low-grade 
tumor. Four (66%) patients had negative microscopic mar-
gins at initial resection. Two cases showed evidence of the 
tumor invading adjacent structures extraluminally. Tumor 
necrosis was present in 5 (84%) tumors. Measurement of 
mitotic rates showed that one tumor was at or below 5/10 
HPF, four tumors were above 5/10 HPF and at or below 
20/10 HPF, and one tumor was above 20/10 HPF. The tu-
mor of the longest-surviving patient (144 months) had a 
unique combination of characteristics showing no ne-
crosis and a low mitotic rate (3/10 HPF) (Table 4). The 
mean follow-up period was 80 months (range, 6 to 118 
months). After resection, all patients developed recur-
rence, and the mean recurrence time was 38 months. And 
the median survival period was 94 months (range, 25 to 
144 months). All patients received adjuvant therapy, com-
prising chemotherapy for one patient, radiotherapy for 
two patients, and chemoradiotherapy for three patients. 
The 3- and 5-year survival rates were 80% and 60%, re-Outcomes of IVC leiomyosarcoma
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Patient no. Adj-CT Adj-RT Local recurrence  Systemic recurrence Recurrence treatment  Status  DFS OS
1Y e s Y e s N o L u n g  
Other muscle
Excision
Excision
Alive 67 132
2 Yes Yes IVC and around organ invasion No Excision Dead 18  36
3N o Y e s N o L u n g
Liver
Excision
CT
Dead 47  97
4N o Y e s N o O t h e r  m u s c l eE x c i s i o n A l i v e 9 1    9 7
5Y e s Y e s N o L u n g  
Other muscle
Bone
Excision
CT
RT
Alive  5  91
6 Yes No No Liver CT Alive  3  25
Adj, adjuvant; CT, chemotherapy; RT, radiotherapy; IVC, inferior vena cava; DFS, disease free survival; OS, overall survival.
Table 5. Summary of adjuvant therapies and recurrences
Fig. 3. Overall survival rate. The 3- and 5-year survival rates were 
80% and 60%, respectively.
spectively (Fig. 3).
There were a total of 15 recurrences in the six patients. 
Local recurrence occurred in one patient (16%) at 18 
months. Distant recurrence occurred in six patients (100%) 
at a median of 40 months. The lung was the most common 
site of distant recurrence (five recurrences in three pa-
tients), followed by the thigh muscle (four recurrences in 
two patients). Surgery was performed for eight recur-
rences in five patients. One lung recurrence was controlled 
using chemotherapy, and one buttock muscle recurrence 
was resolved using radiotherapy. Two patients died at 36 
and 97 months after the first operation, respectively, due to 
multiorgan metastasis (Table 5).
DISCUSSION 
Two thirds of patients with leiomyosarcoma of the IVC 
present with localized disease amenable to curative re-
section [2]. In the present study, five of the six patients 
were female, and all patients had abdominal pain as a pre-
senting symptom. These findings are consistent with 
those described in the Mingoli register which include fe-
male predilection, mean age in the sixth decade, abdomi-
nal pain being a frequent presenting symptom, incon-
sistent association with edema of the lower extremities, 
and potential for development of Budd-Chiari syndrome 
and intracardiac extension [1]. A diagnosis of IVC leio-
myosarcoma can be delayed since the tumors are 
slow-growing and remain confined to the vessel wall in 
the early stages and hence can stay asymptomatic for a 
long time. Discovery is made incidentally in 10.5% of pa-
tients and at autopsy in 33% [3]. 
The most important prognostic indicator for IVC leio-
myosarcoma patients is surgical resection with negative 
margins, which confers a 33 to 68% 5-year survival rate 
[4-7]. The present study found that patients with negative 
margins had a median survival of 86 months. These find-
ings support the view that aggressive resection with neg-
ative margins should be the goal of therapy for those with-
out widespread metastases and who are acceptable surgi-
cal candidates. 
There is little information regarding the efficacy of neo-
adjuvant and adjuvant therapy for IVC leiomyosarcoma, 
and there is no consensus regarding the optimal treatment 
strategy [6]. However, we believe that in the absence of a 
negative margin after resection, survival can be improved 
with the use of appropriate chemotherapy or radio-Jihoon T Kim, et al.
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therapy. The 1999 report from University of California 
quoted a 5-year survival of 53 percent. Those patients re-
ceived adjuvant radiation therapy, which may have im-
proved outcomes [4]. In the present study, negative mar-
gins were not obtained in two patients. However, those pa-
tients remain alive at 97 and 91 months postoperatively. 
Our findings demonstrate that despite high rates of dis-
ease recurrence, long-term survival can be achieved in IVC 
leiomyosarcoma patients. 
Surgical procedures for IVC leiomyosarcoma extir-
pation are frequently complex due to the retro hepatic lo-
cation and close proximity to major branches of the IVC. 
Involvement of the renal vein confluence by the tumor 
may necessitate nephrectomy, kidney auto-transplanta-
tion or re-attachment of the tumor-free renal vein stump to 
the IVC [8]. In the current study, we performed renal vein 
reimplantation on one side and renal vein PTFE graft in-
terposition on the opposite side in three patients, ligation 
of both renal veins in two patients, and vein reimplan-
tation on one side and ligation of the other renal vein in 
one patient. No patient experienced renal impairment.
IVC reconstruction options include placement of a syn-
thetic interposition graft, primary repair, or patch repair of 
the IVC. The proponents of the ligation technique suggest 
that extensive development of the collateral vessels ob-
viates the need for IVC reconstruction, and that patients 
with stable renal function in the presence of complete IVC 
thrombosis tolerate ligation well [9]. Because leiomyo-
sarcoma usually causes gradual obstruction of the IVC lu-
men and formation of collateral veins, IVC resection can 
usually be performed under stable hemodynamic con-
ditions [10]. In our series, IVC reconstruction with PTFE 
was performed in five of the six patients. The remaining 
patient had complete IVC obstruction, dual renal vein in-
volvement and good preoperative renal function. Postop-
eratively, that patient had transient leg edema but no other 
complications. 
One present patient was a 30-year-old female with a tu-
mor located suprahepatic to both iliac veins and involving 
the middle hepatic vein. For this case, we performed ex situ 
en bloc resection IVC with the whole liver, and then hepatic 
vein angioplasty in a bench procedure with the great sa-
phenous vein to make a common channel, and re-
implantation to the PTFE graft. This patient showed good 
postoperative recovery, and no hepatic dysfunction. How-
ever, tumor recurrence as multiple hepatic metastases was 
observed at postoperative three months. To date, she con-
tinues to be treated using chemotherapy, and is currently 
in a stable state.
Debulking may be the only means of tumor control for 
locally advanced primary caval malignancy [3]. This ap-
proach may not only prevent death from liver failure by 
hepatic vein obstruction, but also achieve long-term sur-
vival without venous sequelae. Recent studies indicate ag-
gressive surgical management and adjuvant chemo-
radiotherapy is the best treatment for IVC leiomyosarco-
ma [4]. 
Few publications discuss the management of recurrent 
IVC leiomyosarcoma. As a result, a standardized ap-
proach has not been established. Currently, surgery is the 
only option offered for recurrent disease if associated with 
minimal morbidity, even for isolated metastatic disease. 
The most commonly performed procedure is local ex-
cision for retroperitoneal recurrence and metastasectomy 
for lung recurrence [6,11-16]. Adjuvant chemotherapy 
based on doxorubicin or a combination of doxorubicin 
and ifosfamide may extend the time to recurrence and in-
crease overall survival in sarcoma patients [17,18]. In the 
current study, there were five incidents of lung metastasis 
in three patients, and three incidences of thigh muscle 
metastasis in two patients. One lung metastasis was con-
trolled by doxorubicin plus ifosfamide chemotherapy, and 
another was treated using lung resection. All thigh muscu-
lar metastases involved single sites and were treated using 
simple resection. One buttock muscular metastasis was 
controlled using radiotherapy. Although all six patients 
experienced recurrence, four patients remain alive for an 
average of 80 months. We believe appropriate adjuvant 
chemotherapy or radiotherapy can be effective in disease 
control. 
Although tumor grade, size, and location are well-es-
tablished prognostic factors for sarcomas in general, their 
predictive value for IVC leiomyosarcoma remains to be 
established. Positive surgical margins were predictive of 
worse survival in the series reported by Hines et al. [4]. 
Pathology findings relating to tumor grade, mitotic rate, Outcomes of IVC leiomyosarcoma
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and tumor size have been suggested as possible prog-
nostic factors [6,19]. In the present study, five of the six tu-
mors were high-grade, yet long-term survival was ach-
ieved in most of those patients. However, the small num-
ber of cases in our study prevented meaningful statistical 
analysis regarding prognostic factors. 
In the longest-surviving patient in the current study 
(144 months), the tumor had the unique pathology combi-
nation of no necrosis and a very low mitotic rate (3/10 
HPF). Almost all other tumors had a mitotic rate higher 
than 10/10 HPF and necrosis. Another patient in the pres-
ent study had a tumor that showed very poor pathology 
features: a positive resection margin, high grade mitotic 
rate, ＞70% necrosis, extraluminal growth pattern, and 
anaplastic change associated with recurrent disease. How-
ever, to our surprise, that patient remains alive at post-
operative 91 months. These findings indicate that clini-
cians should be cautious about using pathology factors as 
predictors of survival in IVC leiomyosarcoma patients. 
In conclusion, the present study reported on the use of 
aggressive surgical resection and adjuvant chemo-
radiotherapy for IVC leiomyosarcoma. Although re-
currence occurred in every case, long-term survival was 
achieved, even when tumors showed poor pathology 
features. 
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